

### RTOG 0926

#### Report Based on Data Through: 04/30/2019

### A Phase II Protocol for Patients with Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent with Radiosensitizing Chemotherapy Following a Thorough Transurethral Surgical Re-staging

Institutional TURBT for re-staging	Full-dose Radiation* and	Cystoscopic Surveillance 8-10 weeks after treatment; if
$\rightarrow$	Concurrent Chemotherapy** →	negative, q 3 months for the 1 <sup>st</sup> year, q
		4 months for year 2, q 6 months for
		years 3, 4, and 5*** and then annually
Stage T1 (T1G2 or	* Total dose of 61.2 Gy in 34	***For T1 and Tcis tumor recurrence,
T1G3)	daily fractions	recommend early salvage cystectomy.
		For Ta tumor recurrence, recommend
	** Cisplatin 3 days/week during	either appropriate conservative treatment
	Weeks 1, 3, and 5	or cystectomy.
	-OR-	
	Mitomycin day 1 and 5-fluorouracil	
	Weeks 1 and 4	

<u>Study Chairs:</u>	Douglas M. Dahl, M.D. William U. Shipley, M.D. M. Dror Michaelson, M.D., Ph.D. William Parker, M.Sc, FCCPM Chin-Lee Wu, M.D., Ph.D.	(Urology) (Radiation Oncology) (Medical Oncology) (Medical Physics) (Pathology)		
Protocol Statisticians:	Theodore Karrison, Ph.D.			
	Joseph Rodgers, M.S.			
Research Associate:	Elaine Motyka-Welsh, R.N., M.S.N., C.C.R.P. Roseann Bonanni, C.R.T., C.C.R.P.			
Dosimetrist:	Joanne Hunter, B.S., R.T.(T.)(R.)			
Activated:	11/11/2009			
Closed:	12/20/2017			
Status:	Follow-up, pending primary outcome an	nalysis		

#### • Study Description

This is a one-armed phase II study to evaluate selective bladder preserving concurrent radiation and chemotherapy treatment after transurethral surgical re-staging. Patients must be operable with non-muscle invading tumors and with at least one being a high grade Stage T1 urothelial carcinoma for whom radical cystectomy is being considered as the next conventional step in therapy by standard urologic guidelines. Patients must have AJCC Stages T1, NX or N0, M0 with only transitional cell histology. Patients must be restaged by a urologist in the participating institution with an aggressive, visibly complete TURBT with muscularis propria in the specimen but with no evidence of its invasion by tumor. Patients must have failed standard treatment with, or be medically ineligible for, intravesical biological therapy or chemotherapy. There must be no evidence of prostatic stromal invasion by tumor. The primary endpoint for this study is the three-year rate of freedom from radical cystectomy.

### • Patient Accrual

Accrual was activated on November 11, 2009 and completed on December 20, 2017 with 37 patients enrolled (Table 1 and Figure 1). Accrual to this study was slower than anticipated. As of April 30, 2019, the median time of follow-up for vital status is 5.4 months. The primary analysis will occur in December 2020, after all patients have been followed for a minimum of 3 years.

### • Patient and Tumor Characteristics

There are 3 ineligible patients, two of which did not receive protocol treatment (Tables 2 and 3). Ineligible patients are excluded from analysis. From the remaining patients, two subsequently withdrew consent. The distribution by patient and tumor characteristics is shown in Table 4. Median (min-max) age is 71 years (53-86). Most patients are male (91.2%), white (94.1%), and have a Zubrod performance status = 0 (85.3%).

#### • Adverse Events

AEs were graded with CTCAE version 4. As of April 30, 2019, there have been 20 patients (58.8%) with reported grade 3 events, 1 patient (2.9%) with a reported grade 4 event, and 1 patient (2.9%) with a reported grade 5 event (Table 5). Table 6 shows the distribution of patients by highest grade AE by specific AE term without regard to attribution. This table only includes system organ classes and terms with at least one grade 3, 4, or 5 event. The most common grade 3 events were reported for the investigations (23.5%) system organ class, with decreases in lymphocyte counts as the cause. The one grade 4 AE was a thromboembolic event reported as unlikely related to treatment. Another patient had a grade 4 blood and lymphatic system disorder, as well as a grade 5 chronic kidney disease, which was reported as unrelated to treatment (Table 6). There have been no new grade 5 AEs since the last report.

Table 1
RTOG 0926 Accrual Summary - Data as of 04/30/2019

Targeted sample size:	37
Date activated to accrual:	November 11, 2009
Projected monthly accrual:	1.0 *
Average monthly accrual over the last 6 months:	0.5
Total Accrual:	37
* 0 in first 6 months	

\* 0 in first 6 months.

	<b>3D CRT+Cisplatin</b>
Randomized	37
Ineligible	3
Eligible	34

### Table 2RTOG 0926 Accrual/Eligibility - Data as<br/>of 04/30/2019

Table 3
RTOG 0926 Cases Excluded - Data as of 04/30/2019

	3D CRT+Cisplatin (n=3)			
Reason	n	%		
No protocol treatment	2	66.7		
Ineligible - Not Stage T1	1	33.3		

### Table 4Patient and Tumor Characteristics for Eligible Patients in<br/>RTOG 0926 - Data as of 04/30/2019

	3D CRT+Cisplatin		
Patient or Tumor Characteristic	n	%	
A go (voors)			
Age (years) <=59	4	11.8	
60-69	4	35.3	
70-79	14	41.2	
80+	4	11.8	
Gender			
Male	31	91.2	
Female	3	8.8	
Race			
Black or African American	2	5.9	
White	32	94.1	
Ethnicity			
Not Hispanic or Latino	34	100.0	

	<b>3D CRT+Cisplat</b>		
Patient or Tumor Characteristic	n	%	
Zubrod Performance Status			
0	29	85.3	
1	5	14.7	
Consented to tissue collection			
No	1	2.9	
Yes	33	97.1	
Consented to blood collection			
No	5	14.7	
Yes	29	85.3	
Consented to urine collection			
No	5	14.7	
Yes	29	85.3	
Total	34	100.0	

### Table 4Patient and Tumor Characteristics for Eligible Patients in<br/>RTOG 0926 - Data as of 04/30/2019

3 patients did not have on-study data and are excluded from this table.

## Table 5Distribution of RTOG 0926 Patients by Highest Grade Adverse Eventby System Organ Class - Data as of 04/30/2019For All Reported Adverse Events without Regard to Attribution

	3D CRT+Cisplatin (n=34)				
System Organ Class	n and (%) of Patients by Grade				
	1	2	3	4	5
Overall Highest Grade	2	9	20	1	1
	(5.9)	(26.5)	(58.8)	(2.9)	(2.9)
Blood and lymphatic system disorders	9	5	6	1	0
	(26.5)	(14.7)	(17.6)	(2.9)	(0.0)
Cardiac disorders	0	0	1	0	0
	(0.0)	(0.0)	(2.9)	(0.0)	(0.0)
Ear and labyrinth disorders	2	0	0	0	0
	(5.9)	(0.0)	(0.0)	(0.0)	(0.0)
Eye disorders	2	0	0	0	0
	(5.9)	(0.0)	(0.0)	(0.0)	(0.0)
Gastrointestinal disorders	21	8	4	0	0

	3D CRT+Cisplatin (n=34)n and (%) of Patients by Grade				
System Organ Class				rade	
	1	2	3	4	5
	(61.8)	(23.5)	(11.8)	(0.0)	(0.0)
General disorders and administration site conditions	20	10	2	0	0
	(58.8)	(29.4)	(5.9)	(0.0)	(0.0)
Hepatobiliary disorders	0	0	1	0	0
	(0.0)	(0.0)	(2.9)	(0.0)	(0.0)
Immune system disorders	1	0	0	0	0
	(2.9)	(0.0)	(0.0)	(0.0)	(0.0)
Infections and infestations	0	5	6	0	0
	(0.0)	(14.7)	(17.6)	(0.0)	(0.0)
Injury, poisoning and procedural complications	2	2	0	0	0
	(5.9)	(5.9)	(0.0)	(0.0)	(0.0)
Investigations	6	8	8	0	0
	(17.6)	(23.5)	(23.5)	(0.0)	(0.0)
Metabolism and nutrition disorders	10	9	7	0	0
	(29.4)	(26.5)	(20.6)	(0.0)	(0.0)
Musculoskeletal and connective tissue disorders	9	3	1	0	0
	(26.5)	(8.8)	(2.9)	(0.0)	(0.0)
Nervous system disorders	9	2	2	0	0
	(26.5)	(5.9)	(5.9)	(0.0)	(0.0)
Psychiatric disorders	6	1	2	0	0
	(17.6)	(2.9)	(5.9)	(0.0)	(0.0)
Renal and urinary disorders	10	11	6	0	1
	(29.4)	(32.4)	(17.6)	(0.0)	(2.9)
Reproductive system and breast disorders	3	4	1	0	0
	(8.8)	(11.8)	(2.9)	(0.0)	(0.0)
Respiratory, thoracic and mediastinal disorders	12	1	3	0	0
	(35.3)	(2.9)	(8.8)	(0.0)	(0.0)
Skin and subcutaneous tissue disorders	5	0	0	0	0
	(14.7)	(0.0)	(0.0)	(0.0)	(0.0)
Vascular disorders	1	4	3	1	0
	(2.9)	(11.8)	(8.8)	(2.9)	(0.0)

Table 5
Distribution of RTOG 0926 Patients by Highest Grade Adverse Event
by System Organ Class - Data as of 04/30/2019
For All Reported Adverse Events without Regard to Attribution

Adverse events were graded with CTCAE version 4.

		<b>3D CRT+Cisplatin (n=34)</b>					
System Organ Class/Term	n and (%) of Patients by Grade						
• 0	1	2	3	4	5		
BLOOD AND LYMPHATIC SYSTEM DISORDERS	9	5	6	1	0		
	(26.5)	(14.7)	(17.6)	(2.9)	(0.0)		
Anemia	9	6	5	0	0		
	(26.5)	(17.6)	(14.7)	(0.0)	(0.0)		
Blood and lymphatic system disorders - Other	0	0	1	1	0		
	(0.0)	(0.0)	(2.9)	(2.9)	(0.0)		
Febrile neutropenia	0	0	1	0	0		
	(0.0)	(0.0)	(2.9)	(0.0)	(0.0)		
CARDIAC DISORDERS	0	0	1	0	0		
	(0.0)	(0.0)	(2.9)	(0.0)	(0.0)		
Atrial fibrillation	0	0	1	0	0		
	(0.0)	(0.0)	(2.9)	(0.0)	(0.0)		
GASTROINTESTINAL DISORDERS	21	8	4	0	0		
	(61.8)	(23.5)	(11.8)	(0.0)	(0.0)		
Diarrhea	15	4	2	0	0		
	(44.1)	(11.8)	(5.9)	(0.0)	(0.0)		
Duodenal ulcer	0	0	1	0	0		
	(0.0)	(0.0)	(2.9)	(0.0)	(0.0)		
Enterocolitis	0	0	1	0	0		
	(0.0)	(0.0)	(2.9)	(0.0)	(0.0)		
Gastrointestinal disorders - Other	4	1	1	0	0		
	(11.8)	(2.9)	(2.9)	(0.0)	(0.0)		
Lower gastrointestinal hemorrhage	0	0	1	0	0		
	(0.0)	(0.0)	(2.9)	(0.0)	(0.0)		
Mucositis oral	3	0	1	0	0		
	(8.8)	(0.0)	(2.9)	(0.0)	(0.0)		
GENERAL DISORDERS AND ADMINISTRATION SITE							
CONDITIONS	20	10	2	0	0		
	(58.8)	(29.4)	(5.9)	(0.0)	(0.0)		
Non-cardiac chest pain	0	0	1	0	0		
	(0.0)	(0.0)	(2.9)	(0.0)	(0.0)		
Pain	3	2	1	0	0		
	(8.8)	(5.9)	(2.9)	(0.0)	(0.0)		
HEPATOBILIARY DISORDERS	0	0	1	0	0		
	(0.0)	(0.0)	(2.9)	(0.0)	(0.0)		
Hepatobiliary disorders - Other	0	0	1	0	0		
	(0.0)	(0.0)	(2.9)	(0.0)	(0.0)		
INFECTIONS AND INFESTATIONS	0	5	6	0	0		
	(0.0)	(14.7)	(17.6)	(0.0)	(0.0)		
Lung infection	0	0	1	0	0		
	(0.0)	(0.0)	(2.9)	(0.0)	(0.0)		
Tooth infection	0	0	1	0	0		

## Table 6Distribution of RTOG 0926 Patients by Highest Grade Adverse Event<br/>by Specific Adverse Event Term - Data as of 04/30/2019<br/>For Selected Adverse Events without Regard to Attribution

System Organ Class/Term	<b>3D CRT+Cisplatin (n=34)</b>					
	n and (%) of Patients by Grade					
	1	2	3	4	5	
	(0.0)	(0.0)	(2.9)	(0.0)	(0.0)	
Urinary tract infection	0	3	4	0	0	
	(0.0)	(8.8)	(11.8)	(0.0)	(0.0)	
INVESTIGATIONS	6	8	8	0	0	
	(17.6)	(23.5)	(23.5)	(0.0)	(0.0)	
Lymphocyte count decreased	2	6	8	0	0	
	(5.9)	(17.6)	(23.5)	(0.0)	(0.0)	
Neutrophil count decreased	1	2	2	0	0	
*	(2.9)	(5.9)	(5.9)	(0.0)	(0.0)	
White blood cell decreased	9	2	1	0	0	
	(26.5)	(5.9)	(2.9)	(0.0)	(0.0)	
METABOLISM AND NUTRITION DISORDERS	10	9	7	0	0	
	(29.4)	(26.5)	(20.6)	(0.0)	(0.0)	
Dehydration	0	3	2	0	0	
	(0.0)	(8.8)	(5.9)	(0.0)	(0.0)	
Hyperglycemia	9	5	1	0	0	
	(26.5)	(14.7)	(2.9)	(0.0)	(0.0)	
Hyperkalemia	1	2	1	0	0	
	(2.9)	(5.9)	(2.9)	(0.0)	(0.0)	
Hypoalbuminemia	5	2	1	0	0	
	(14.7)	(5.9)	(2.9)	(0.0)	(0.0)	
Hypomagnesemia	4	0	1	0	0	
	(11.8)	(0.0)	(2.9)	(0.0)	(0.0)	
Hyponatremia	5	0	2	0	0	
	(14.7)	(0.0)	(5.9)	(0.0)	(0.0)	
Hypophosphatemia	1	2	1	0	0	
	(2.9)	(5.9)	(2.9)	(0.0)	(0.0)	
MUSCULOSKELETAL AND CONNECTIVE TISSUE						
DISORDERS	9	3	1	0	0	
	(26.5)	(8.8)	(2.9)	(0.0)	(0.0)	
Back pain	2	0	1	0	0	
	(5.9)	(0.0)	(2.9)	(0.0)	(0.0)	
NERVOUS SYSTEM DISORDERS	9	2	2	0	0	
	(26.5)	(5.9)	(5.9)	(0.0)	(0.0)	
Stroke	0	0	1	0	0	
	(0.0)	(0.0)	(2.9)	(0.0)	(0.0)	
Syncope	0	0	1	0	0	
	(0.0)	(0.0)	(2.9)	(0.0)	(0.0)	
PSYCHIATRIC DISORDERS	6	1	2	0	0	
	(17.6)	(2.9)	(5.9)	(0.0)	(0.0)	
Confusion	0	0	1	0	0	
	(0.0)	(0.0)	(2.9)	(0.0)	(0.0)	
Insomnia	4	0	1	0	0	

# Table 6Distribution of RTOG 0926 Patients by Highest Grade Adverse Eventby Specific Adverse Event Term - Data as of 04/30/2019For Selected Adverse Events without Regard to Attribution

	3	3D CRT+Cisplatin (n=34)					
System Organ Class/Term	n and (%) of Patients by Grade				rade		
	1	2	3	4	5		
	(11.8)	(0.0)	(2.9)	(0.0)	(0.0)		
RENAL AND URINARY DISORDERS	10	11	6	0	1		
	(29.4)	(32.4)	(17.6)	(0.0)	(2.9)		
Chronic kidney disease	0	1	0	0	1		
	(0.0)	(2.9)	(0.0)	(0.0)	(2.9)		
Hematuria	3	3	5	0	0		
	(8.8)	(8.8)	(14.7)	(0.0)	(0.0)		
Renal calculi	0	0	1	0	0		
	(0.0)	(0.0)	(2.9)	(0.0)	(0.0)		
Urinary tract obstruction	0	1	1	0	0		
	(0.0)	(2.9)	(2.9)	(0.0)	(0.0)		
Urinary tract pain	3	0	1	0	0		
	(8.8)	(0.0)	(2.9)	(0.0)	(0.0)		
REPRODUCTIVE SYSTEM AND BREAST DISORDERS	3	4	1	0	0		
	(8.8)	(11.8)	(2.9)	(0.0)	(0.0)		
Reproductive system and breast disorders - Other	0	0	1	0	0		
	(0.0)	(0.0)	(2.9)	(0.0)	(0.0)		
RESPIRATORY, THORACIC AND MEDIASTINAL							
DISORDERS	12	1	3	0	0		
	(35.3)	(2.9)	(8.8)	(0.0)	(0.0)		
Aspiration	0	0	1	0	0		
	(0.0)	(0.0)	(2.9)	(0.0)	(0.0)		
Dyspnea	9	1	2	0	0		
	(26.5)	(2.9)	(5.9)	(0.0)	(0.0)		
Нурохіа	0	1	2	0	0		
	(0.0)	(2.9)	(5.9)	(0.0)	(0.0)		
VASCULAR DISORDERS	1	4	3	1	0		
	(2.9)	(11.8)	(8.8)	(2.9)	(0.0)		
Hypotension	1	1	1	0	0		
	(2.9)	(2.9)	(2.9)	(0.0)	(0.0)		
Thromboembolic event	0	2	1	1	0		
	(0.0)	(5.9)	(2.9)	(2.9)	(0.0)		
Vascular disorders - Other	0	0	1	0	0		
	(0.0)	(0.0)	(2.9)	(0.0)	(0.0)		

## Table 6Distribution of RTOG 0926 Patients by Highest Grade Adverse Eventby Specific Adverse Event Term - Data as of 04/30/2019For Selected Adverse Events without Regard to Attribution

Adverse events were graded with CTCAE version 4.

Only includes system organ classes and terms with at least one grade 3, 4, or 5.




Figure 1 Cumulative Accrual for RTOG 0926 - Data as of 04/30/2019